Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003305 · ClinicalTrials.gov registry record · Phase 2
Aminopterin in Treating Patients With Refractory Leukemia
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00003305 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 75 participants.
The verdict
NCT00003305, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory leukemia.
Interventions
- DRUG leucovorin calcium
- DRUG aminopterin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1997-07 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003305
The ClinicalTrials.gov registry entry for NCT00003305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which leucovorin calcium is the first listed.
NCT00003305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003305 about?
NCT00003305 is a clinical study titled "Aminopterin in Treating Patients With Refractory Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminopterin in treating patients who have refractory leukemia.
What is the current status of trial NCT00003305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1997-07. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00003305?
The interventions under investigation include: leucovorin calcium (DRUG), aminopterin (DRUG).
Who is sponsoring clinical trial NCT00003305?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.